Newsroom

Newsroom

August 1, 2021
Announcement
Research, Education

External Advisory Board adds new members

August 1, 2021
Research, Education
Announcement
Prominent kidney cancer experts Elizabeth Plimack, M.D., M.S., and Rana McKay, M.D.,
Elizabeth Plimack, M.D., M.S. (left) and Rana McKay, M.D.

Prominent kidney cancer experts Elizabeth Plimack, M.D., M.S., and Rana McKay, M.D., are the newest members of the Kidney Cancer Program’s External Advisory Board. Established in 2014, the nine-member board comprises noted physicians and scientists from across the country who serve as resources on research initiatives for KCP leadership.

Dr. Plimack is Professor of Hematology/Oncology and Division Chief of Genitourinary Medical Oncology at Fox Chase Cancer Center in Philadelphia. Dr. McKay is Associate Professor of Medicine and Urology at the University of California-San Diego and Co-Leader of the Genitourinary Oncology Disease Team at Moores Cancer Center.

UTSW investigator identifies signaling pathway responsible for driving sarcomatoid differentiation

June 3, 2021
Research, Discovery
Publications

Molecular biologist Thomas Carroll, Ph.D., reports in the Journal of Clinical Investigation that activation of the Hippo/Warts pathway, one of the major signaling pathways regulating organ size and tissue growth, is sufficient to drive sarcomatoid renal cancer. In studies in mice, Carroll and colleagues show that constitutive activation of Hippo/Warts through deletion of Lats1/2 drives sarcomatoid tumors and metastases.

April 14, 2021
Lecture
Research, HIF2, Targeted Drugs

2019 Nobel Prize winner Dr. William Kaelin speaks at University Lecture Series

April 14, 2021
Research, HIF2, Targeted Drugs
Lecture

2019 Nobel Prize winner and Harvard Medical School Professor William Kaelin, M.D., is the guest speaker for UT Southwestern’s University Lecture Series. Kidney Cancer Program Director James Brugarolas, M.D., Ph.D., and Associate Professor of Pathology Qing Zhang, Ph.D., served as hosts. Dr. Kaelin is recognized for his landmark work involving the VHL tumor suppressor gene.

March 30, 2021
Event
Research, SPORE, Technology Development

KCP hosts seventh annual Advisory Board meeting

March 30, 2021
Research, SPORE, Technology Development
Event
Members of the Kidney Cancer Program’s External Scientific Advisory Board convened to discuss the program’s latest research initiatives and proposed SPORE projects.

Members of the Kidney Cancer Program’s External Scientific Advisory Board convened to discuss the program’s latest research initiatives and proposed SPORE projects.

February 8, 2021
Publications
Research, Discovery, Immunotherapy

New immunotherapy drug boosts innate immune system to fight cancer

February 8, 2021
Research, Discovery, Immunotherapy
Publications

A newly released study in Nature Biomedical Engineering by Jinming Gao, Professor of Oncology, Pharmacology, and Otolarynology, shows how a novel, nanoparticle-based drug may be more effective at engaging the body’s innate immune system to fight cancer. The drug’s unique and prolonged binding to the STING protein was associated with longer innate immune activation, demonstrating a more effective T cell response against solid tumors. PRESS RELEASE

November 5, 2020
Publications
Research, Discovery

Novel ccRCC evolutionary model

November 5, 2020
Research, Discovery
Publications
Drawing from a recent report of ccRCC subtypes based on gene expression (from a Genentech-sponsored clinical trial), as well as pioneering genomic discoveries and mouse models from the Kidney Cancer Program, Drs. Brugarolas and Kapur present an updated evolutionary model of clear cell renal cell carcinoma development. Article

Drawing from a recent report of ccRCC subtypes based on gene expression (from a Genentech-sponsored clinical trial), as well as pioneering genomic discoveries and mouse models from the Kidney Cancer Program, Drs. Brugarolas and Kapur present an updated evolutionary model of clear cell renal cell carcinoma development. Article